Agree with your figure. Thanks. One would hope the new commercial chief can help re-accelerate the tysabri growth, now that the community has a better handle on incidence rate and management of PML.
agree I think elan is pretty fairly valued at $3-$4 Billion. Of course, if bapineuzumab works, then that value could triple. i don't see anything too interesting in their pipeline besides bapineuzumab, and since the ph 2 failed, it is very risky
Market Data 
Markets 
AI
